Gastrointestinal cancer metastatic
RecruitingStudy of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment
Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment
- Disease:Gastrointestinal cancer metastatic
- Substances:SunitinibVelzatinib
France- Participants:18–64 years · 65+ years
- Substances:Sunitinib
- Sponsor:Glaxosmithkline Research & Development Limited










